drugset / Trial / NCT01372163
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
RandomizedParallel-groupTriple-blindBasic science
Summary
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.
Timeline
- Start
- 2011-07
- Primary completion
- 2012-04
- Completion
- 2012-04
Outcome
Outcome not reported
Stopped (Business): “B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns leading to discontinuation of this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-5190457 | Small molecule | 2 mg | Oral |
| Subject | PF-5190457 | Small molecule | 5 mg | Oral |
| Subject | PF-5190457 | Small molecule | 10 mg | Oral |
| Subject | PF-5190457 | Small molecule | 40 mg | Oral |
| Subject | PF-5190457 | Small molecule | 50 mg | Oral |
| Subject | PF-5190457 | Small molecule | 150 mg | Oral |